PTGS2 and early-onset autosomal dominant Alzheimer disease: Preclinically, COX-2 inhibitors significantly improve synaptic and cognitive dysfunction in Alzheimer’s disease mouse models (Kotilinek et al., 2008), and marijuana-induced addiction (Chen et al., 2013).